JP2014533259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533259A5 JP2014533259A5 JP2014540560A JP2014540560A JP2014533259A5 JP 2014533259 A5 JP2014533259 A5 JP 2014533259A5 JP 2014540560 A JP2014540560 A JP 2014540560A JP 2014540560 A JP2014540560 A JP 2014540560A JP 2014533259 A5 JP2014533259 A5 JP 2014533259A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- nhc
- treatment
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 230000004064 dysfunction Effects 0.000 claims 8
- -1 hydrate Chemical class 0.000 claims 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 7
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 6
- 206010003662 Atrial flutter Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims 4
- 208000001435 Thromboembolism Diseases 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 210000001013 sinoatrial node Anatomy 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 230000033228 biological regulation Effects 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 206010040639 Sick sinus syndrome Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 210000001992 atrioventricular node Anatomy 0.000 claims 2
- 230000011128 cardiac conduction Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 239000000960 hypophysis hormone Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000005968 oxazolinyl group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000007368 endocrine function Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 230000003557 neuropsychological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000006008 trihaloethoxy group Chemical group 0.000 claims 1
- 125000006004 trihaloethyl group Chemical group 0.000 claims 1
- 125000004951 trihalomethoxy group Chemical group 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1119703.5A GB201119703D0 (en) | 2011-11-15 | 2011-11-15 | Compounds |
| GB1119703.5 | 2011-11-15 | ||
| GB1214250.1 | 2012-08-09 | ||
| GBGB1214250.1A GB201214250D0 (en) | 2012-08-09 | 2012-08-09 | Compounds |
| PCT/GB2012/052842 WO2013072694A1 (en) | 2011-11-15 | 2012-11-15 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014533259A JP2014533259A (ja) | 2014-12-11 |
| JP2014533259A5 true JP2014533259A5 (enExample) | 2016-01-14 |
Family
ID=47222145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540560A Pending JP2014533259A (ja) | 2011-11-15 | 2012-11-15 | カリウムチャネル阻害剤として有用なチエノおよびフロピリミジンならびにピリジン |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9290511B2 (enExample) |
| EP (1) | EP2780343A1 (enExample) |
| JP (1) | JP2014533259A (enExample) |
| KR (1) | KR20140094603A (enExample) |
| CN (1) | CN104011054B (enExample) |
| AR (1) | AR090037A1 (enExample) |
| AU (1) | AU2012338570A1 (enExample) |
| BR (1) | BR112014011671A2 (enExample) |
| CA (1) | CA2855346A1 (enExample) |
| IN (1) | IN2014MN01183A (enExample) |
| MX (1) | MX2014005935A (enExample) |
| RU (1) | RU2014124101A (enExample) |
| TW (1) | TWI498331B (enExample) |
| WO (1) | WO2013072694A1 (enExample) |
| ZA (1) | ZA201403503B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509989VA (en) | 2013-06-06 | 2016-01-28 | Astellas Pharma Inc | Benzothiophene compound |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| RU2545758C1 (ru) * | 2014-03-20 | 2015-04-10 | Общество с ограниченной ответственностью "Алион" | Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| CN106727587A (zh) * | 2016-11-28 | 2017-05-31 | 李娜 | 一种治疗心律失常的药物组合物 |
| EP3562828B1 (en) | 2016-12-28 | 2026-03-18 | Dart Neuroscience LLC | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| EP3668841B1 (en) * | 2017-08-14 | 2026-07-08 | Acesion Pharma Aps | Substituted benzimidazoles as potassium channel inhibitors |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
| CN108117556A (zh) * | 2018-01-15 | 2018-06-05 | 王山川 | 一种细胞周期检查点激酶1抑制剂的合成方法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| WO2022194191A1 (en) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12d |
| EP4313973A1 (en) * | 2021-03-22 | 2024-02-07 | Acesion Pharma ApS | Novel potassium channel inhibitors |
| JP2024511801A (ja) * | 2021-03-26 | 2024-03-15 | スミトモ ファーマ オンコロジー， インコーポレイテッド | （フロピリミジン－４－イル）ピペラジン化合物及びその使用 |
| CA3218259A1 (en) * | 2021-04-30 | 2022-11-03 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
| CN115006468B (zh) * | 2022-06-28 | 2023-06-06 | 西安外事学院 | 一种复方中草药生发液及制备方法 |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
| AU651337B2 (en) * | 1990-03-30 | 1994-07-21 | Dowelanco | Thienopyrimidine derivatives |
| WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
| WO2004011057A1 (en) | 1998-02-07 | 2004-02-05 | Advanced Cardiovascular Systems, Inc. | Perfusion dilatation catherer with expanded support coil |
| JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
| WO2001021610A1 (en) | 1999-09-17 | 2001-03-29 | Nissan Chemical Industries, Ltd. | Benzopyran derivative |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| DE10031585A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 2-Aminoalkyl-thieno[2,3-d]pyrimidine |
| TW589305B (en) | 2001-02-14 | 2004-06-01 | Nissan Chemical Ind Ltd | 4-aminobenzopyran derivatives |
| IL159218A0 (en) | 2001-06-25 | 2004-06-01 | Nissan Chemical Ind Ltd | Substituted benzopyran derivatives against arrhythmia |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AU2002333524A1 (en) * | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| GB0315950D0 (en) * | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| CN1823071B (zh) * | 2003-06-11 | 2012-12-19 | 润生有限公司 | 用作钾通道抑制剂的噻吩并嘧啶衍生物 |
| US7594219B2 (en) | 2003-07-24 | 2009-09-22 | International Business Machines Corporation | Method and apparatus for monitoring compatibility of software combinations |
| TWI346112B (en) | 2004-02-25 | 2011-08-01 | Nissan Chemical Ind Ltd | Benzopyran compound |
| TW200609237A (en) * | 2004-04-12 | 2006-03-16 | Sankyo Co | Thienopyridine derivatives |
| CA2568304A1 (en) | 2004-06-10 | 2005-12-22 | Xention Discovery Limited | Furanopyrimidine compounds effective as potassium channel inhibitors |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006047397A1 (en) | 2004-10-21 | 2006-05-04 | Dow Agrosciences Llc | Thieno-pyrimidine compounds having fungicidal activity |
| US7576212B2 (en) * | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
| ATE476434T1 (de) * | 2004-12-09 | 2010-08-15 | Xention Ltd | Thienopyridinderivate als kaliumkanalinhibitoren |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| CA2595882A1 (en) | 2005-01-26 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
| WO2006100591A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| EP1896483A2 (en) | 2005-03-28 | 2008-03-12 | Pharmacia & Upjohn Company LLC | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CA2602538A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CA2602227A1 (en) | 2005-03-28 | 2006-10-05 | Michael Dalton Ennis | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| AU2006261082B2 (en) * | 2005-06-22 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| US7816351B2 (en) * | 2005-09-23 | 2010-10-19 | Equispharm Co., Ltd | 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus |
| US20070213305A1 (en) * | 2005-11-02 | 2007-09-13 | Cytovia, Inc. | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| EP2043654A2 (en) * | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
| DE102006030236A1 (de) | 2006-06-30 | 2008-01-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
| TW200924781A (en) * | 2007-09-14 | 2009-06-16 | Janssen Pharmaceutica Nv | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| PL2254873T3 (pl) | 2008-02-22 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek benzodiazepinowy i kompozycja farmaceutyczna |
| US20100227853A1 (en) | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| BRPI0918971A2 (pt) * | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| TWI334124B (en) * | 2008-08-28 | 2010-12-01 | Au Optronics Corp | Display drive circuit for flat panel display and driving method for gate lines |
| TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| AR073739A1 (es) | 2008-09-10 | 2010-12-01 | Kalypsys Inc | Aminopirimidinas como inhibidores de los receptores de histamina |
| WO2010033127A1 (en) | 2008-09-22 | 2010-03-25 | Sionyx, Inc. | Response-enhanced monolithic-hybrid pixel |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| JP5619907B2 (ja) | 2009-10-29 | 2014-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
| CA2788450A1 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
| TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2012
- 2012-11-14 AR ARP120104296A patent/AR090037A1/es unknown
- 2012-11-15 RU RU2014124101/04A patent/RU2014124101A/ru not_active Application Discontinuation
- 2012-11-15 US US14/358,722 patent/US9290511B2/en not_active Expired - Fee Related
- 2012-11-15 AU AU2012338570A patent/AU2012338570A1/en not_active Abandoned
- 2012-11-15 MX MX2014005935A patent/MX2014005935A/es not_active Application Discontinuation
- 2012-11-15 KR KR1020147015757A patent/KR20140094603A/ko not_active Withdrawn
- 2012-11-15 CN CN201280061286.3A patent/CN104011054B/zh not_active Expired - Fee Related
- 2012-11-15 EP EP12790948.9A patent/EP2780343A1/en not_active Withdrawn
- 2012-11-15 JP JP2014540560A patent/JP2014533259A/ja active Pending
- 2012-11-15 TW TW101142693A patent/TWI498331B/zh not_active IP Right Cessation
- 2012-11-15 CA CA2855346A patent/CA2855346A1/en not_active Abandoned
- 2012-11-15 BR BR112014011671A patent/BR112014011671A2/pt not_active IP Right Cessation
- 2012-11-15 WO PCT/GB2012/052842 patent/WO2013072694A1/en not_active Ceased
-
2014
- 2014-05-14 ZA ZA2014/03503A patent/ZA201403503B/en unknown
-
2015
- 2015-03-16 IN IN1183MUN2014 patent/IN2014MN01183A/en unknown
-
2016
- 2016-02-05 US US15/016,846 patent/US20160152634A1/en not_active Abandoned